Ligand Pharmaceuticals (LGND) EBITDA Margin (2010 - 2026)
Ligand Pharmaceuticals (LGND) posted EBITDA Margin of 33.58% for Q1 2026, up 44.73% sequentially from 23.2% in Q4 2025, and up 11347.0% YoY from N/an in Q1 2025.
Ligand Pharmaceuticals (LGND) EBITDA Margin (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported EBITDA Margin for 17 years, with the latest figure at 33.58% in Q1 2026.
- Quarterly EBITDA Margin rose 11347.0% year-over-year to 33.58% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 34.46% (up 6852.0% YoY) and the FY2025 annual result came in at 15.29%, up 2882.0% from the prior year.
- EBITDA Margin improved to 33.58% in Q1 2026 per LGND's latest filing, from 23.2% in the prior quarter.
- Over five years, EBITDA Margin peaked at 47.58% in Q3 2025 and troughed at 79.89% in Q1 2025.
- A 5-year average of 0.92% and a median of 9.36% in 2023 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2022 and 2026: EBITDA Margin tumbled 10671 bps in 2022, then surged 11347 bps in 2026.
- Over 5 years, EBITDA Margin stood at 39.89% in 2022, then soared by 70 bps to 11.95% in 2023, then plunged by 88 bps to 22.51% in 2024, then surged by 203 bps to 23.2% in 2025, then soared by 45 bps to 33.58% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 33.58%, 23.2%, and 47.58% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | 13.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.49% |
| Mar 31, 2026 | 33.58% |
| Dec 31, 2025 | 23.20% |
| Sep 30, 2025 | 47.58% |
| Jun 30, 2025 | 17.73% |
| Mar 31, 2025 | -79.89% |
| Dec 31, 2024 | -22.51% |
| Sep 30, 2024 | 6.07% |
| Jun 30, 2024 | -45.99% |
| Mar 31, 2024 | 9.65% |
| Dec 31, 2023 | -11.95% |
| Sep 30, 2023 | 9.36% |
| Jun 30, 2023 | -7.52% |
| Mar 31, 2023 | 32.30% |
| Dec 31, 2022 | -39.89% |
| Sep 30, 2022 | 20.84% |
| Jun 30, 2022 | 17.28% |
| Mar 31, 2022 | 5.84% |
| Dec 31, 2021 | 66.82% |
| Sep 30, 2021 | 26.31% |